公开(公告)号：US20030050234A1

公开(公告)日：2003-03-13

申请号：US09910009

申请日：2001-07-23

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Baldomero M. Olivera ,  J. Michael McIntosh ,  James E. Garrett ,  Maren Watkins ,  Lourdes J. Cruz ,  Ki-Joon Shon ,  Richard B. Jacobsen ,  Robert M. Jones ,  G. Edward Cartier ,  Gregory S. Shen ,  John D. Wagstaff

IPC: A61K038/17 ,  C07K014/435

CPC classification number: C07K14/43504 ,  A61K38/00

Abstract: The present invention is to null-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the null-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The null-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the null-conopeptides and encoding propeptides, as well as the propeptides.

Abstract translation: 本发明涉及多肽，其衍生物或药学上可接受的盐。 本发明还涉及该肽，其衍生物和其药学上可接受的盐在治疗与电压门控钠通道相关的疾病中的用途。 因此，μ-肽或衍生物可用作神经肌肉阻滞剂，局部麻醉剂，止痛剂和神经保护剂。 多肽也可用于治疗神经肌肉疾病。 本发明还涉及编码多肽的核酸序列和编码前肽以及前肽。

公开(公告)号：US20040259794A1

公开(公告)日：2004-12-23

申请号：US10887203

申请日：2004-07-09

Applicant: Cognetix, Inc. ,  University of Utah Research Foundation

Inventor： Baldomero M. Olivera ,  J. Michael McIntosh ,  R. Tyler McCabe ,  James E. Garrett ,  Richard T. Layer ,  John D. Wagstaff ,  Robert M. Jones

IPC: A61K038/17

CPC classification number: C07K14/43504 ,  A61K38/17

Abstract: The present invention is directed to the new nullO-conopeptides, their coding sequences and their propeptides and to the use of nullO-conopeptides as a local anesthetic for treating pain. The nullO-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.

Abstract translation: 本发明涉及新的muO-肽，它们的编码序列及其前肽，以及使用muO-肽作为局部麻醉剂治疗疼痛。 muO-肽具有持久的麻醉活性，对于脊髓麻醉特别有用，无论是急性用于术后疼痛还是通过鞘内泵用于严重慢性疼痛情况或用于治疗上皮组织中的疼痛。

公开(公告)号：US20040204362A1

公开(公告)日：2004-10-14

申请号：US10839179

申请日：2004-05-06

Applicant: The University of Utah Research Foundation ,  Cognetix, Inc.

Inventor： Baldomero M. Olivera ,  Richard T. Layer ,  Maren Watkins ,  David R. Hillyard ,  J. Michael McIntosh ,  Robert Schoenfeld ,  Jacob Scott Nielsen ,  Robert M. Jones

IPC: A61K038/17 ,  C07K014/435 ,  C07H021/04

CPC classification number: C07K14/435 ,  A61K38/00 ,  C07K14/43504

Abstract: The invention relates to relatively short peptides (termed null-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The null-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.

Abstract translation: 本发明涉及相对短的肽（本文中称为α-芋螺毒素），长度约10-25个残基，其在锥形蜗牛的毒液中天然可以微量天然存在或类似于天然可得的肽，并且其优选包括两个 二硫键。 如本文所述，α-蛇毒毒素可用作神经肌肉阻滞剂，例如肌肉松弛剂。

公开(公告)号：US20030224343A1

公开(公告)日：2003-12-04

申请号：US10352254

申请日：2003-01-28

Applicant: University of Utah Research Foundation ,  Cognetix, Inc.

Inventor： Karen Pemberton-Goodman ,  Robert M. Jones ,  Davis L. Temple JR. ,  J. Michael McIntosh ,  Baldomero M. Olivera

IPC: A01N001/02 ,  A61K038/16

CPC classification number: A01N1/0226 ,  A01N1/02 ,  A61K38/17 ,  A61K38/49 ,  C07K14/435 ,  G01N2500/00 ,  A61K2300/00

Abstract: The invention relates to null-PVIIA-related conotoxins and their use as organ protecting agents, i.e., organ protectants. These conotoxins can be used for arresting, protecting or preserving an organ, such as a circulatory organ, a respiratory organ, a urinary organ, a digestive organ, a reproductive organ, an endocrine organ or a neurological organ. These conotoxins can also be used for arresting, protecting or preserving somatic cells.

Abstract translation: 本发明涉及kappa-PVIIA相关的芋螺毒素及其作为器官保护剂即器官保护剂的用途。 这些芋螺毒素可用于阻滞，保护或保存器官，如循环器官，呼吸器官，尿器官，消化器官，生殖器官，内分泌器官或神经器官。 这些芋螺毒素也可用于阻滞，保护或保存体细胞。

公开(公告)号：US20030170222A1

公开(公告)日：2003-09-11

申请号：US10058053

申请日：2002-01-29

Applicant: University of Utah Research Foundation

Inventor： Robert M. Jones ,  Baldomero M. Olivera ,  Maren Watkins ,  James E. Garrett

IPC: A61K038/17 ,  A61K038/43 ,  C07K014/435

CPC classification number: C07K14/43504

Abstract: The present invention is directed to null-superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the null-superfamily conotoxin peptides and encoding null-superfamily conotoxin propeptides, as well as the null-superfamily conotoxin propeptides.

Abstract translation: 本发明涉及β-超家族荚果毒素肽，其衍生物或药学上可接受的盐。 本发明进一步涉及该肽，其衍生物和其药学上可接受的盐在治疗与电压门控离子通道，配体门控通道和其它受体相关的病症中的用途。 本发明还涉及编码β-超家族荚果毒素肽和编码β-超家族荚果毒素前肽以及β-超家族荚果毒素前肽的核酸序列。

公开(公告)号：US20030109670A1

公开(公告)日：2003-06-12

申请号：US10072602

申请日：2002-02-11

Applicant: University of Utah Research Foundation

Inventor： Baldomero M. Olivera ,  J. Michael McIntosh ,  Maren Watkins ,  James E. Garrett ,  Lourdes J. Cruz ,  Michelle Grilley ,  Robert A. Schoenfeld ,  Craig S. Walker ,  Reshma P. Shetty ,  Robert M. Jones

IPC: A61K038/00 ,  C07K005/00 ,  C07K016/00 ,  C07K007/00 ,  C07K017/00 ,  C07H021/04 ,  C12N001/20 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N005/00 ,  C12N005/02

CPC classification number: C07K14/43504 ,  A61K38/00

Abstract: The present invention is directed to conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, voltage-gated ligand channels and/or receptors. The invention is further directed to nucleic acid sequences encoding the conotoxin peptides and encoding propeptides, as well as the propeptides.

Abstract translation: 本发明涉及芋螺毒素肽，其衍生物或药学上可接受的盐。 本发明进一步涉及该肽，其衍生物和其药学上可接受的盐在治疗与电压门控离子通道，电压门控配体通道和/或受体相关的病症中的用途。 本发明还涉及编码芋螺毒素肽和编码前肽以及前肽的核酸序列。

公开(公告)号：US20030065138A1

公开(公告)日：2003-04-03

申请号：US10092367

申请日：2002-03-07

Applicant: University of Utah Research Foundation

Inventor： Baldomero M. Olivera ,  J. Michael McIntosh ,  James E. Garrett ,  Craig S. Walker ,  Maren Watkins ,  Robert M. Jones

IPC: C07K007/08 ,  C07K014/435

CPC classification number: C07K14/43504 ,  A61K38/00

Abstract: The invention relates to linear null-carboxyglutamate rich conotoxins, derivatives or pharmaceutically acceptable salts thereof, and uses thereof, including the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, as neuroprotective agents or for the management of pain. The invention further relates to nucleic acid sequences encoding the conopeptides and encoding propeptides, as well as the propeptides.

Abstract translation: 本发明涉及线性γ-羧基谷氨酸富含芋螺毒素，其衍生物或其药学上可接受的盐及其用途，包括治疗神经系统疾病和精神病学疾病，如抗惊厥剂，神经保护剂或用于治疗疼痛。 本发明还涉及编码肽和编码前肽以及前肽的核酸序列。

公开(公告)号：US20030050435A1

公开(公告)日：2003-03-13

申请号：US09908741

申请日：2001-07-20

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Baldomero M. Olivera ,  Richard T. Layer ,  Maren Watkins ,  David R. Hillyard ,  J. Michael McIntosh ,  Robert Schoenfeld ,  Jacob Scott Nielsen ,  Robert M. Jones

IPC: A61K038/17 ,  C07K014/435 ,  C07H021/04

CPC classification number: C07K14/43504 ,  A61K38/00

Abstract: The invention relates to relatively short peptides (termed null-conotoxins herein), about 10-25 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. The null-conotoxins, as described herein, are useful for as neuromuscular blocking agents, such as muscle relaxants.

Abstract translation: 本发明涉及相对短的肽（本文中称为α-芋螺毒素），长度约10-25个残基，其在锥形蜗牛的毒液中天然可以微量天然存在或类似于天然可得的肽，并且其优选包括两个 二硫键。 如本文所述，α-蛇毒毒素可用作神经肌肉阻滞剂，例如肌肉松弛剂。

公开(公告)号：US20020102607A1

公开(公告)日：2002-08-01

申请号：US09894882

申请日：2001-06-29

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Craig S. Walker ,  Reshma Shetty ,  Elsie C. Jimenez ,  J. Michael McIntosh ,  Baldomero M. Olivera ,  Maren Watkins ,  Robert M. Jones ,  Gregory S. Shen

IPC: A01N037/18 ,  A61K038/00 ,  G01N033/53 ,  A61K038/16 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  C07K001/00 ,  C07K014/00

CPC classification number: C07K14/43504

Abstract: The invention relates to relatively short peptides (termed I-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.

Abstract translation: 本发明涉及相对短的肽（本文中称为I-芋螺毒素），长度约30-50个残基，其在锥形蜗牛的毒液中天然可以微量天然存在或类似于天然可得的肽，并且优选包括四个 二硫键。

公开(公告)号：US20040192886A1

公开(公告)日：2004-09-30

申请号：US10828478

申请日：2004-04-21

Applicant: The University of Utah Research Foundation ,  Cognetix, Inc.

Inventor： Baldomero M. Olivera ,  J. Michael McIntosh ,  James E. Garrett ,  Maren Watkins ,  Lourdes J. Cruz ,  Ki-Joon Shon ,  Richard B. Jacobsen ,  Robert M. Jones ,  G. Edward Cartier ,  Gregory S. Shen ,  John D. Wagstaff

IPC: A61K038/17 ,  C07K014/47

CPC classification number: C07K14/43504 ,  A61K38/00

Abstract: The present invention is to null-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the null-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The null-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the null-conopeptides and encoding propeptides, as well as the propeptides.

Abstract translation: 本发明涉及多肽，其衍生物或药学上可接受的盐。 本发明还涉及该肽，其衍生物和其药学上可接受的盐在治疗与电压门控钠通道相关的疾病中的用途。 因此，μ-肽或衍生物可用作神经肌肉阻滞剂，局部麻醉剂，止痛剂和神经保护剂。 多肽也可用于治疗神经肌肉疾病。 本发明还涉及编码多肽的核酸序列和编码前肽以及前肽。